Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court ruling allows Shiley valve patient to sue for fraud, breach of express warranty.

This article was originally published in The Gray Sheet

Executive Summary

SHILEY VALVE PATIENT CHARGES OF FRAUD, BREACH OF EXPRESS WARRANTY are being remanded to the U.S. District Court in Philadelphia, where a jury will review the charges based on Pennsylvania state law. The legal evaluation of the two charges made by Bjork-Shiley valve recipient Nina Michael is moving back to district court following an Oct. 2 denial by the U.S. Supreme Court to review a petition submitted by Shiley and parent Pfizer. Shiley had asked the high court to overturn the ruling of the Third Circuit Court of Appeals, which concluded that federal law does not preempt the express warranty and fraud charges, thereby allowing Michael to sue under state law. The Supreme Court declined to review the petition without comment.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel